Sarah Ghosh

Immunotherapy/Lung Cancer 🫁 | MBA | Alum of @uchicago and @columbia_biz | NYC | Views are my own.

[Sarah Ghosh @SarahGhosh20]

Blast from the past working with the emergency helicopter team at @UChicagoMed. I was so excited to be at the ‘forefront of medicine’! Circa 2007

[Ben Creelan, MD MS @BenCreelan]

Happy to be here at #ASCO26 for an excellent NSCLC session hosted by Dr. @BrunaPellini !

Hoping to find HARMONi?🧘
Sing a LIBRETTO? 🎤
Earn your CROWN?
Become an ALCHEMIST?
Wield a TRITON?

Look forward to these trials and more!

[OncoAlert @OncoAlert]

Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact

https://t.co/cMipRjLkzy

Reviews advances in #LungCancer 🫁, #mesothelioma , and thymic epithelial malignancies from 2005 to 2025, highlighting the impact of translational science on diagnosis, prognosis, and treatment. It emphasizes tumor heterogeneity 🧬 immune and genomic biomarkers guiding therapy, and the growing role of germline genetics in risk assessment and screening.
Distinct molecular subtypes of mesothelioma enable tailored treatments, while emerging biological insights are improving management of rare thymic tumors.

@AmosChrisa
@dean_fennell
@GalateauF
@LGiannakou
@t_mitsudomi
@LBadia5364
@APassaroMD
@peters_solange
@hilaryarobbins
@ChristianRolfo
@ScherpereelA
@yang_haining
@harvey_pass

Ping
OncoAlert Lung Cancer Faculty
@GlopesMd @NarjustFlorezMD @StephenVLiu @bmassutis @peters_solange @UmbertoMalapel1 @g_mountzios @christine_lovly @jillfeldman4 @DrSanjayPopat

#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

🫁 Poor PS, high PD-L1—can IO still work?

IFCT-1802 SAVIMMUNE (Ph2) evaluated 1L durvalumab in stage IV #NSCLC with ECOG PS 2–3 & PD-L1 ≥25%.

◼️ Grade ≥3 TRAEs (8 wks): 10%
◼️ ORR: 26%
◼️ 1-yr OS: 40%
◼️ PS improvement at 8 wks: 44%

Important data for a population often excluded from trials. @LungCancerRx @OncoAlert @oncodaily
@JTOonline https://t.co/slBfnKXnLc

[Vivek Subbiah, MD @VivekSubbiah]

Why cancer can come back years later — and how to stop it https://t.co/xR8zF4FzQE

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

Check our viewpoint published @JAMA_current #MedEd

Abstract Factory—Research Culture Harming Medical Education

The "abstract factory" is destroying medical education. Trainees and junior faculty compete with abstract counts instead of meaningful research. Result: inflated CVs, diluted conferences. We shouldn't celebrate this—you don't need publications to be a great doctor.

➡️https://t.co/IMBhy45L1K

@utswcancer @rajshekharucms @HiraSMian @ManniMD1 @HemOncFellows @ASCOTECAG

[Balazs Halmos @BalazsHalmosMD]

Happiest Thanksgiving turkey and many positive trials, onc friends!
#lcsm

[Mara Antonoff, MD, FACS @maraantonoff]

In this @AATSJournals article with @MDAndersonNews @lungoncdoc, we discuss clinicians’ responsibility to educate: Clear and evidence based messaging shape patient understanding, and social media is an important venue for sharing accurate information. https://t.co/mCNveIeC8n

[Eric K. Singhi, MD @lungoncdoc]

On the stage at our inaugural #PRIMONYLung25 discussing important 1L clinical updates for patients with mNSCLC without AGAs.

Key pts discussed:
-Can’t just lump all “high PDL1” dz
-STK11/KEAP1 matter
-Squamous histology impactful
-5yr OS rates informative

[Bruna Pellini, MD @BrunaPellini]

🚨 Exciting moment at #PrimONYLung25!
@lungoncdoc takes the stage to dive into the role of #ChemoIO in metastatic #NSCLC.
Cutting-edge insights shaping the future of lung cancer care. 💡🫁 @christinemphmd @OnvivCompany

[Chul Kim @chulkimMD]

When lung cancer is diagnosed early, survival rates are much higher.

We must continue to advance therapies—but the greatest impact will likely come from earlier detection.

@LungAssociation

[Bruna Pellini, MD @BrunaPellini]

🤩Great to connect with colleagues and friends at #WCLC25 — science, collaboration, and friendships that keep moving the field forward. 📸✨

[Balazs Halmos @BalazsHalmosMD]

How most us feel after 5 dizzying days of #WCLC25

#Picasso

[Balazs Halmos @BalazsHalmosMD]

Oncologists
Arriving at ASCO
Returning from ASCO

#ASCO25

[Bruna Pellini, MD @BrunaPellini]

🚨If you were not at #ASCO25 for ASCO Highlights today, you must stream @lungoncdoc excellent presentation! Very informative!

[Sarah Ghosh @SarahGhosh20]

@Jani_Chinmay @lungoncdoc You’re welcome. Taking appointments for headshots, slots filling up 😂

[Chinmay Jani @Jani_Chinmay]

#ASCO25 - @OncLive Fellows forum is more than just learning #LungCancer. We make friends, learn from mentors and celebrate birthdays @BenBleibergMD while enjoying great views in Chicago! @benlevylungdoc @SWaliany @KalantriShreyas @dominicandoc2 @SarahGhosh20

[Stephen V Liu, MD @StephenVLiu]

5 year outcomes with 1L cemiplimab vs chemo in PD-L1 high NSCLC from phase III EMPOWER-Lung 1 @JTOonline. OS favors cempilimab (26.1 vs 13.3m, HR 0.59, 5y OS rate 29% vs 15%) with better outcomes for PD-L1 ≥ 90%, where mOS 38.8m, 5y OS rate 39.8%.

https://t.co/ho0yWyWNEB

[Yuji Uehara, MD, PhD @DrYujiUehara]

⏰ Timing might matter in NSCLC! A bi-continental study shows morning immuno-chemotherapy (before 11:30 AM) nearly doubled survival vs afternoon dosing (33.0 vs 19.5 months). RWE from France & China—time to rethink the schedule of immunotherapy! https://t.co/9JhZEnoyZz

[Eric K. Singhi, MD @lungoncdoc]

Honored to join @FOX26Houston this morning to shed light on the rising rates of lung cancer in patients with no smoking history. The message remains the same: all you need to be at risk for lung cancer is to have lungs!

@MDAndersonNews #EndCancer

[gilberto lopes @GlopesMd]

https://t.co/sjY17xnyCa
Our meta-analysis aggregates data from more the 30 studies comprising 3000+ patients, showing that ctDNA decrease and clearance are strongly associated with PFS and OS in lung cancer. Results hold true for targeted treatments and immunotherapy! @iaslc #LCSM @GuardantHealth @LucenceHealth @ASCO @uicc Time is ripe to include as outcome in prospective studies so we can incorporate in decision making and drug approval process - @FDAOncology @JCOGO_ASCO @ASCOPost @JackWestMD @n8pennell @ChristianRolfo @StephenVLiu @myESMO @SylvesterCancer @cancermd @NarjustFlorezMD @Jani_Chinmay @Latinamd